Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (Symptomatic nOH) in Subjects With Primary Autonomic Failure

NCT04095793 is registered in ClinicalTrials.gov with Theravance Biopharma as lead sponsor.

NCT NCT04095793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04095793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (Symptomatic nOH) in Subjects With Primary Autonomic Failure
Lead sponsor
Theravance Biopharma
Phase
Phase 3
Overall status
Terminated
Start date
September 19, 2019
Completion date
November 12, 2021
Enrollment
110 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

symptomatic neurogenic orthostatic hypotension